Follicular lymphoma (FL) is a common and indolent lymphoma.The recently studies show that FL displays heterogeneity for clinical process and biological prognostic biomarkers.A large class FL patient is asymptomatic with indolent course which are vulnerable to the toxic chemo-therapies.However,a subset of FL develop chemo-resistance and undergo a transformation to aggressive lymphoma.These subtypes are needed for new therapies and alternative approaches.Following new biomarkers had been discovered,previous clinical prognostic indices for FL become limited.In this review,we introduce the clinical prognostic index in FL and novel prognostic markers for evaluating poor risk.A useful incorporation both clinical and molecular determinants for the risk stratification of FL will help to identify high-risk FL at diagnosis and choose rational targeted therapies.